



CARDIAC SURGERY | SATELLITE SYMPOSIUM TREATMENT OF MITRAL REGURGITATION ACROSS THE PATIENT SPECTRUM. THE FUTURE IS NOW.

> FRI 04 OCT | 12:30-13:45 EACTS - ROOM 5A

## CARDIAC SURGERY | SATELLITE SYMPOSIUM

## TREATMENT OF

## MITRAL REGURGITATION ACROSS THE PATIENT SPECTRUM. THE FUTURE IS NOW.

FRI 04 OCT | 12:30-13:45 | ROOM 5A

MODERATORS O. Alfieri (Milan, Italy),

J. L. Pomar (Barcelona, Spain)

## **PRESENTATIONS**

Title	Speaker
Minimally invasive mitral valve surgery: a reliable therapeutic solution	A. Anselmi

(Rennes, France) for long term outcomes.

The impact of recent clinical evidence and innovation on MitraClip M. Taramasso (Zurich, Switzerland) patient selection considerations.

First 100 Patients Treated with the Tendyne Transcatheter Mitral Prosthesis: T. Walther (Frankfurt, Germany) Results from the Global Feasibility Study/CE Mark Trial.

Tendyne is currently pending CE mark. Not available for sale.

Unless otherwise specified, all product and service names appearing herein are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress may be made without the prior written authorization of Abbott. Products intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use provided inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Photo(s) on file at Abbott. Information contained herein is for distribution for Europe, Middle East and Africa ONLY. Please check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force. Not intended for physicians from France.

Abbott International BVBA, Park Lane, Culliganlaan 2b, 1831 Diegem, Belgium, Tel: +32 2 714 14 11

